PCSK9 inhibitors
Pronunciation: PEE-see-ess-kay-nine
A class of cholesterol-lowering drugs that block proprotein convertase subtilisin/kexin type 9.
Full Definition
PCSK9 inhibitors are monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9, an enzyme that regulates LDL cholesterol receptor degradation. These drugs significantly reduce LDL cholesterol levels and are used in cardiovascular research as both therapeutic interventions and primary endpoints. They represent a newer class of lipid-lowering therapy beyond traditional statins. In clinical trials, editors must distinguish between different PCSK9 inhibitor drugs and their mechanisms of action.
Usage
Usage note: Always specify the particular PCSK9 inhibitor (e.g., evolocumab, alirocumab) when mentioned in clinical contexts.
In Context
- "The trial demonstrated that PCSK9 inhibitors reduced major adverse cardiovascular events by 15% compared to placebo." — Clinical trial manuscript
- "Secondary endpoints included changes in LDL cholesterol levels following PCSK9 inhibitor administration." — Study protocol